WE HAVE BEEN PROVEN RIGHT ON AMPYRA FROM ACORDA THERAPEUTICS

Today Acorda Therapeutics (ACOR) reported earnings. Acorda stock has risen on hopes for blockbuster sales of its MS walking drug Ampyra. First the stock went higher,  but started falling when investors realized that sales will drop ...
Read more »

EXITING ACOR WITH PROFIT RIGHT HERE AT $32.61.

Our negative thesis on Acordia Therapeutics (ACOR) has not changed.  However we are positive on the group, therefore we will exit the entire position right here and plan to short again on spikes up.  For ...
Read more »

ADDING TO $ACOR (ACORDA THERAPEUTICS) SHORT SALE POSITION HERE AT $38.15

www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since 2007, without exception, is included in the performance results. Number of ...
Read more »

AS PER PRIOR POST, ADDING TO $ACOR (ACORDIA) SHORT AT $33.37

www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since 2007, without exception, is included in the performance results. Number of ...
Read more »

UPDATE ON OPEN INDIVIDUAL STOCK POSITIONS

We are exiting $BCRX and $AVAV; please see separate posts for the reasons.We are short on $ACOR with average price of $30.28. Our thesis has not changed in that Ampyra is not a very good ...
Read more »

WOW! FDA AGREES WITH OUR LONGSTANDING ASSESSMENT OF FAMPRIDINE-SR , SHORT SELL $ACOR (ACORDIA) PER OUR PRIOR POST

www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since 2007, without exception, is included in the performance results. Number of ...
Read more »

ACOR (ACORDIA) FAMPRIDINE IS NOT A VERY GOOD DRUG EVEN IF IT WORKS AS ADVERTISED

The FDA Peripheral and Central Nervous System Drugs Advisory Committee meets today to review ACOR's Fampridine-SR for improvement of walking in patients with multiple sclerosis .We have been negative on ACOR from the very beginning ...
Read more »
Follow

Get every new post delivered to your Inbox

Join other followers